Interferon-λs: Front-line guardians of immunity and homeostasis in the respiratory tract

Frontiers in Immunology

Volumn 8, Issue SEP, 2017, Pages

  Andreakos, Evangelos ^a   Salagianni, Maria ^a   Galani, Ioanna E ^a   Koltsida, Ourania ^a  

^a BIOMEDICAL RESEARCH FOUNDATION   (Greece)

Author keywords

Asthma; Cytokines; Infection; Innate immunity; Interferons; Respiratory tract diseases

Indexed keywords

CORTICOSTEROID; INTERLEUKIN 28; INTERLEUKIN 29; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9;

ALLERGIC DISEASE; ANTIMICROBIAL ACTIVITY; ANTIVIRAL ACTIVITY; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC RESPIRATORY TRACT DISEASE; EPIGENETICS; GASTROINTESTINAL TRACT; GENE OVEREXPRESSION; HOMEOSTASIS; HUMAN; IMMUNITY; INFLUENZA; NONHUMAN; POSTTRANSCRIPTIONAL GENE SILENCING; PROTEIN EXPRESSION; RESPIRATORY SYSTEM; SHORT SURVEY; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UPREGULATION; VIRAL RESPIRATORY TRACT INFECTION; VIRUS LOAD; VIRUS RESISTANCE;

EID: 85030178951     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2017.01232     Document Type: Short Survey

References (74)

1. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci (1957) 147(927):258-67. doi:10.1098/rspb.1957.0048
2. Wheelock EF. Interferon-like virus-inhibitor induced in human leukocytes by phytohemagglutinin. Science (1965) 149(3681):310-1. doi:10.1126/science.149.3681.310
3. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol (2003) 4(1):69-77. doi:10.1038/ni875
4. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol (2003) 4(1):63-8. doi:10.1038/ni873
5. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 45(2):164-71. doi:10.1038/ng.2521
6. Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev (2004) 202:8-32. doi:10.1111/j.0105-2896.2004.00204.x
7. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol (2004) 75(2):163-89. doi:10.1189/jlb.0603252
8. Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol (2014) 32:513-45. doi:10.1146/annurev-immunol-032713-120231
9. Boxx GM, Cheng G. The roles of type I interferon in bacterial infection. Cell Host Microbe (2016) 19(6):760-9. doi:10.1016/j.chom.2016.05.016
10. Liehl P, Zuzarte-Luis V, Chan J, Zillinger T, Baptista F, Carapau D, et al. Host-cell sensors for Plasmodium activate innate immunity against liver-stage infection. Nat Med (2014) 20(1):47-53. doi:10.1038/nm.3424
11. McNab F, Mayer-Barber K, Sher A, Wack A, O'Garra A. Type I interferons in infectious disease. Nat Rev Immunol (2015) 15(2):87-103. doi:10.1038/nri3787
12. Galani IE, Koltsida O, Andreakos E. Type III interferons (IFNs): emerging master regulators of immunity. Adv Exp Med Biol (2015) 850:1-15. doi:10.1007/978-3-319-15774-0_1
13. Wack A, Terczynska-Dyla E, Hartmann R. Guarding the frontiers: the biology of type III interferons. Nat Immunol (2015) 16(8):802-9. doi:10.1038/ni.3212
14. Lazear HM, Nice TJ, Diamond MS. Interferon-lambda: immune functions at barrier surfaces and beyond. Immunity (2015) 43(1):15-28. doi:10.1016/j.immuni.2015.07.001
15. Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, Paludan SR. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol (2006) 80(9):4501-9. doi:10.1128/JVI.80.9.4501-4509.2006
16. Odendall C, Dixit E, Stavru F, Bierne H, Franz KM, Durbin AF, et al. Diverse intracellular pathogens activate type III interferon expression from peroxisomes. Nat Immunol (2014) 15(8):717-26. doi:10.1038/ni.2915
17. Bierne H, Travier L, Mahlakoiv T, Tailleux L, Subtil A, Lebreton A, et al. Activation of type III interferon genes by pathogenic bacteria in infected epithelial cells and mouse placenta. PLoS One (2012) 7(6):e39080. doi:10.1371/journal.pone.0039080
18. Iwasaki A, Pillai PS. Innate immunity to influenza virus infection. Nat Rev Immunol (2014) 14(5):315-28. doi:10.1038/nri3665
19. Spann KM, Tran KC, Chi B, Rabin RL, Collins PL. Suppression of the induction of alpha, beta, and lambda interferons by the NS1 and NS2 proteins of human respiratory syncytial virus in human epithelial cells and macrophages [corrected]. J Virol (2004) 78(8):4363-9. doi:10.1128/JVI.78.8.4363-4369.2004
20. Ank N, Iversen MB, Bartholdy C, Staeheli P, Hartmann R, Jensen UB, et al. An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. J Immunol (2008) 180(4):2474-85. doi:10.4049/jimmunol.180.4.2474
21. Sommereyns C, Paul S, Staeheli P, Michiels T. IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog (2008) 4(3):e1000017. doi:10.1371/journal.ppat.1000017
22. Coccia EM, Severa M, Giacomini E, Monneron D, Julkunen I, Cella M, et al. Viral infection and toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur J Immunol (2004) 34(3):796-805. doi:10.1002/eji.200324610
23. Siegel R, Eskdale J, Gallagher G. Regulation of IFN-lambda1 promoter activity (IFN-lambda1/IL-29) in human airway epithelial cells. J Immunol (2011) 187(11):5636-44. doi:10.4049/jimmunol.1003988
24. Kotenko SV. IFN-lambdas. Curr Opin Immunol (2011) 23(5):583-90. doi:10.1016/j.coi.2011.07.007
25. Durbin RK, Kotenko SV, Durbin JE. Interferon induction and function at the mucosal surface. Immunol Rev (2013) 255(1):25-39. doi:10.1111/imr.12101
26. Bolen CR, Ding S, Robek MD, Kleinstein SH. Dynamic expression profiling of type I and type III interferon-stimulated hepatocytes reveals a stable hierarchy of gene expression. Hepatology (2014) 59(4):1262-72. doi:10.1002/hep.26657
27. Kohli A, Zhang X, Yang J, Russell RS, Donnelly RP, Sheikh F, et al. Distinct and overlapping genomic profiles and antiviral effects of interferon-lambda and-alpha on HCV-infected and non-infected hepatoma cells. J Viral Hepat (2012) 19(12):843-53. doi:10.1111/j.1365-2893.2012.01610.x
28. Crotta S, Davidson S, Mahlakoiv T, Desmet CJ, Buckwalter MR, Albert ML, et al. Type I and type III interferons drive redundant amplification loops to induce a transcriptional signature in influenza-infected airway epithelia. PLoS Pathog (2013) 9(11):e1003773. doi:10.1371/journal.ppat.1003773
29. Zhou Z, Hamming OJ, Ank N, Paludan SR, Nielsen AL, Hartmann R. Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J Virol (2007) 81(14):7749-58. doi:10.1128/JVI.02438-06
30. Doyle SE, Schreckhise H, Khuu-Duong K, Henderson K, Rosler R, Storey H, et al. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology (2006) 44(4):896-906. doi:10.1002/hep.21312
31. Contoli M, Message SD, Laza-Stanca V, Edwards MR, Wark PA, Bartlett NW, et al. Role of deficient type III interferon-lambda production in asthma exacerbations. Nat Med (2006) 12(9):1023-6. doi:10.1038/nm1462
32. Galani IE, Triantafyllia V, Eleminiadou EE, Koltsida O, Stavropoulos A, Manioudaki M, et al. Interferon-lambda mediates non-redundant front-line antiviral protection against influenza virus infection without compromising host fitness. Immunity (2017) 46(5):875-890e6. doi:10.1016/j.immuni.2017.04.025
33. Pott J, Mahlakoiv T, Mordstein M, Duerr CU, Michiels T, Stockinger S, et al. IFN-lambda determines the intestinal epithelial antiviral host defense. Proc Natl Acad Sci U S A (2011) 108(19):7944-9. doi:10.1073/pnas.1100552108
34. Hernandez PP, Yang I, Schwierzeck V, Nguyen N, Guendel F, Gronke K, et al. Interferon-lambda and interleukin 22 act synergistically for the induction of interferon-stimulated genes and control of rotavirus infection. Nat Immunol (2015) 16(7):698-707. doi:10.1038/ni.3180
35. Mahlakoiv T, Hernandez P, Gronke K, Diefenbach A, Staeheli P. Leukocyte-derived IFN-alpha/beta and epithelial IFN-lambda constitute a compartmentalized mucosal defense system that restricts enteric virus infections. PLoS Pathog (2015) 11(4):e1004782. doi:10.1371/journal.ppat.1004782
36. Nice TJ, Baldridge MT, McCune BT, Norman JM, Lazear HM, Artyomov M, et al. Interferon-lambda cures persistent murine norovirus infection in the absence of adaptive immunity. Science (2015) 347(6219):269-73. doi:10.1126/science.1258100
37. Lin JD, Feng N, Sen A, Balan M, Tseng HC, McElrath C, et al. Distinct roles of type I and type III interferons in intestinal immunity to homologous and heterologous rotavirus infections. PLoS Pathog (2016) 12(4):e1005600. doi:10.1371/journal.ppat.1005600
38. Okabayashi T, Kojima T, Masaki T, Yokota S, Imaizumi T, Tsutsumi H, et al. Type-III interferon, not type-I, is the predominant interferon induced by respiratory viruses in nasal epithelial cells. Virus Res (2011) 160(1-2):360-6. doi:10.1016/j.virusres.2011.07.011
39. Spann KM, Baturcam E, Schagen J, Jones C, Straub CP, Preston FM, et al. Viral and host factors determine innate immune responses in airway epithelial cells from children with wheeze and atopy. Thorax (2014) 69(10):918-25. doi:10.1136/thoraxjnl-2013-204908
40. Wang J, Oberley-Deegan R, Wang S, Nikrad M, Funk CJ, Hartshorn KL, et al. Differentiated human alveolar type II cells secrete antiviral IL-29 (IFN-lambda 1) in response to influenza A infection. J Immunol (2009) 182(3):1296-304. doi:10.4049/jimmunol.182.3.1296
41. Yang K, Puel A, Zhang S, Eidenschenk C, Ku CL, Casrouge A, et al. Human TLR-7-,-8-, and-9-mediated induction of IFN-alpha/beta and-lambda is IRAK-4 dependent and redundant for protective immunity to viruses. Immunity (2005) 23(5):465-78. doi:10.1016/j.immuni.2005.09.016
42. Lauterbach H, Bathke B, Gilles S, Traidl-Hoffmann C, Luber CA, Fejer G, et al. Mouse CD8alpha+ DCs and human BDCA3 + DCs are major producers of IFN-lambda in response to poly IC. J Exp Med (2010) 207(12):2703-17. doi:10.1084/jem.20092720
43. Trinchieri G. Type I interferon: friend or foe? J Exp Med (2010) 207(10):2053-63. doi:10.1084/jem.20101664
44. Wang BX, Fish EN. The Yin and Yang of viruses and interferons. Trends Immunol (2012) 33(4):190-7. doi:10.1016/j.it.2012.01.004
45. Jewell NA, Cline T, Mertz SE, Smirnov SV, Flano E, Schindler C, et al. Lambda interferon is the predominant interferon induced by influenza A virus infection in vivo. J Virol (2010) 84(21):11515-22. doi:10.1128/JVI.01703-09
46. Mordstein M, Kochs G, Dumoutier L, Renauld JC, Paludan SR, Klucher K, et al. Interferon-lambda contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses. PLoS Pathog (2008) 4(9):e1000151. doi:10.1371/journal.ppat.1000151
47. Mordstein M, Neugebauer E, Ditt V, Jessen B, Rieger T, Falcone V, et al. Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J Virol (2010) 84(11):5670-7. doi:10.1128/JVI.00272-10
48. Mahlakoiv T, Ritz D, Mordstein M, DeDiego ML, Enjuanes L, Muller MA, et al. Combined action of type I and type III interferon restricts initial replication of severe acute respiratory syndrome coronavirus in the lung but fails to inhibit systemic virus spread. J Gen Virol (2012) 93(Pt 12):2601-5. doi:10.1099/vir.0.046284-0
49. Wang Y, Li T, Chen Y, Wei H, Sun R, Tian Z. Involvement of NK cells in IL-28B-mediated immunity against influenza virus infection. J Immunol (2017) 199(3):1012-20. doi:10.4049/jimmunol.1601430
50. Souza-Fonseca-Guimaraes F, Young A, Mittal D, Martinet L, Bruedigam C, Takeda K, et al. NK cells require IL-28R for optimal in vivo activity. Proc Natl Acad Sci U S A (2015) 112(18):E2376-84. doi:10.1073/pnas.1424241112
51. Paolini R, Bernardini G, Molfetta R, Santoni A. NK cells and interferons. Cytokine Growth Factor Rev (2015) 26(2):113-20. doi:10.1016/j.cytogfr.2014.11.003
52. Davidson S, Crotta S, McCabe TM, Wack A. Pathogenic potential of interferon alphabeta in acute influenza infection. Nat Commun (2014) 5:3864. doi:10.1038/ncomms4864
53. Davidson S, McCabe TM, Crotta S, Gad HH, Hessel EM, Beinke S, et al. IFNlambda is a potent anti-influenza therapeutic without the inflammatory side effects of IFNalpha treatment. EMBO Mol Med (2016) 8(9):1099-112. doi:10.15252/emmm.201606413
54. Maher SG, Sheikh F, Scarzello AJ, Romero-Weaver AL, Baker DP, Donnelly RP, et al. IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity. Cancer Biol Ther (2008) 7(7):1109-15. doi:10.4161/cbt.7.7.6192
55. Jilg N, Lin W, Hong J, Schaefer EA, Wolski D, Meixong J, et al. Kinetic differences in the induction of interferon stimulated genes by interferon-alpha and interleukin 28B are altered by infection with hepatitis C virus. Hepatology (2014) 59(4):1250-61. doi:10.1002/hep.26653
56. Galani IE, Andreakos E. Neutrophils in viral infections: current concepts and caveats. J Leukoc Biol (2015) 98(4):557-64. doi:10.1189/jlb.4VMR1114-555R
57. Mantovani A, Cassatella MA, Costantini C, Jaillon S. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol (2011) 11(8):519-31. doi:10.1038/nri3024
58. Tecchio C, Micheletti A, Cassatella MA. Neutrophil-derived cytokines: facts beyond expression. Front Immunol (2014) 5:508. doi:10.3389/fimmu.2014.00508
59. Broggi A, Tan Y, Granucci F, Zanoni I. IFN-lambda suppresses intestinal inflammation by non-translational regulation of neutrophil function. Nat Immunol (2017) 18:1084-93. doi:10.1038/ni.3821
60. Koltsida O, Hausding M, Stavropoulos A, Koch S, Tzelepis G, Ubel C, et al. IL-28A (IFN-lambda2) modulates lung DC function to promote Th1 immune skewing and suppress allergic airway disease. EMBO Mol Med (2011) 3(6):348-61. doi:10.1002/emmm.201100142
61. Bullens DM, Decraene A, Meyts I, De Boeck K, Dupont LJ, Ceuppens JL. Type III IFN-lambda mRNA expression in sputum of adult and school-aged asthmatics. Clin Exp Allergy (2008) 38(9):1459-67. doi:10.1111/j.1365-2222.2008.03045.x
62. Jordan WJ, Eskdale J, Srinivas S, Pekarek V, Kelner D, Rodia M, et al. Human interferon lambda-1 (IFN-lambda1/IL-29) modulates the Th1/Th2 response. Genes Immun (2007) 8(3):254-61. doi:10.1038/sj.gene.6364382
63. Dai J, Megjugorac NJ, Gallagher GE, Yu RY, Gallagher G. IFN-lambda1 (IL-29) inhibits GATA3 expression and suppresses Th2 responses in human naive and memory T cells. Blood (2009) 113(23):5829-38. doi:10.1182/blood-2008-09-179507
64. Mennechet FJ, Uze G. Interferon-lambda-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells. Blood (2006) 107(11):4417-23. doi:10.1182/blood-2005-10-4129
65. Dolganiuc A, Kodys K, Marshall C, Saha B, Zhang S, Bala S, et al. Type III interferons, IL-28 and IL-29, are increased in chronic HCV infection and induce myeloid dendritic cell-mediated FoxP3+ regulatory T cells. PLoS One (2012) 7(10):e44915. doi:10.1371/journal.pone.0044915
66. Megjugorac NJ, Gallagher GE, Gallagher G. Modulation of human plasmacytoid DC function by IFN-lambda1 (IL-29). J Leukoc Biol (2009) 86(6):1359-63. doi:10.1189/jlb.0509347
67. Yin Z, Dai J, Deng J, Sheikh F, Natalia M, Shih T, et al. Type III IFNs are produced by and stimulate human plasmacytoid dendritic cells. J Immunol (2012) 189(6):2735-45. doi:10.4049/jimmunol.1102038
68. Zhang S, Kodys K, Li K, Szabo G. Human type 2 myeloid dendritic cells produce interferon-lambda and amplify interferon-alpha in response to hepatitis C virus infection. Gastroenterology (2013) 144(2):414-425e7. doi:10.1053/j.gastro.2012.10.034
69. Edwards MR, Regamey N, Vareille M, Kieninger E, Gupta A, Shoemark A, et al. Impaired innate interferon induction in severe therapy resistant atopic asthmatic children. Mucosal Immunol (2013) 6(4):797-806. doi:10.1038/mi.2012.118
70. Wark PA, Johnston SL, Bucchieri F, Powell R, Puddicombe S, Laza-Stanca V, et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med (2005) 201(6):937-47. doi:10.1084/jem.20041901
71. Jackson DJ, Sykes A, Mallia P, Johnston SL. Asthma exacerbations: origin, effect, and prevention. J Allergy Clin Immunol (2011) 128(6):1165-74. doi:10.1016/j.jaci.2011.10.024
72. Djukanovic R, Harrison T, Johnston SL, Gabbay F, Wark P, Thomson NC, et al. The effect of inhaled IFN-beta on worsening of asthma symptoms caused by viral infections. A randomized trial. Am J Respir Crit Care Med (2014) 190(2):145-54. doi:10.1164/rccm.201312-2235OC
73. Mallia P, Message SD, Gielen V, Contoli M, Gray K, Kebadze T, et al. Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation. Am J Respir Crit Care Med (2011) 183(6):734-42. doi:10.1164/rccm.201006-0833OC
74. Wu W, Zhang W, More S, Booth JL, Duggan ES, Liu L, et al. Cigarette smoke attenuates the RIG-I-initiated innate antiviral response to influenza infection in two murine models. Am J Physiol Lung Cell Mol Physiol (2014) 307(11):L848-58. doi:10.1152/ajplung.00158.2014